Seiichi Hayato (he/him/his)

Associate Director
Eisai, Japan

Poster(s):

• (T-074) Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Patients with Solid Tumors
  Tuesday, October 21, 2025

  7:00 AM - 1:45 PM MDT